Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee

NCT03513016 is registered in ClinicalTrials.gov with Unity Biotechnology, Inc. as lead sponsor.

NCT NCT03513016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03513016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
Lead sponsor
Unity Biotechnology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 16, 2018
Completion date
April 12, 2019
Enrollment
78 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee